Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma - Wikidata - awgldk - TriplyDB

Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma

Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma

http://www.wikidata.org/entity/Q33183686

about

The peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol ester Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity.A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8 Nuclear receptor profile in calvarial bone cells undergoing osteogenic versus adipogenic differentiation The piggyBac transposon-mediated expression of SV40 T antigen efficiently immortalizes mouse embryonic fibroblasts (MEFs).Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells.Therapeutic Implications of PPARgamma in Human Osteosarcoma.Bone morphogenetic protein-9 effectively induces osteo/odontoblastic differentiation of the reversibly immortalized stem cells of dental apical papilla E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα.Decellularized liver scaffolds effectively support the proliferation and differentiation of mouse fetal hepatic progenitors.Lysophosphatidic acid acyltransferase β (LPAATβ) promotes the tumor growth of human osteosarcoma.Conditionally immortalized mouse embryonic fibroblasts retain proliferative activity without compromising multipotent differentiation potential.Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer Defective osteogenic differentiation in the development of osteosarcoma.Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system.Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation.The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.Peroxisome proliferator activated receptor γ protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation.Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells.The Current and Future Therapies for Human Osteosarcoma.Osteosarcoma development and stem cell differentiation PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.Molecular basis of differentiation therapy for soft tissue sarcomas.Effects of Tributyltin Chloride on Cybrids with or without an ATP Synthase Pathologic Mutation.The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway.BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model

P2860

Q24806798-1BFD9806-A232-4587-928E-74D7E394905C Q28540201-4FBE87DE-7B4D-496F-80F9-0218D6F7746C Q30414471-D0824F04-E506-4C78-AA94-D2A22E9AF70B Q33197120-111A0A2F-A5ED-4B87-A44B-DFBF69C94CEF Q33475497-E4C8981B-9741-4412-B241-A3AF8C33B3E3 Q33532809-149EAADA-BE46-4A0C-AEB9-650DF58D6836 Q33563694-371685D1-B1F0-4450-8FE0-6933991F55F8 Q33638231-7F1CD1A4-7450-43AA-9F47-44407806F339 Q33651188-3C759BE8-AA0D-4EC3-BEC0-D660E2B3CD59 Q33674615-DBD17A3C-A50D-4511-99EF-9B92459D5DB7 Q33713821-A62A00E4-E41B-40F4-940D-2EDEC3E1E6B6 Q33728384-3104BD5B-3AAF-40B5-A88E-1C030D052DBB Q33751404-52AB9E48-17CE-4F31-9ADA-A77FE0FDFF01 Q33769959-41317993-9EF6-4378-B5AA-FD22BE09A0D4 Q34182685-96143A83-9EA8-4BB8-BC86-191BC9D3181E Q34552005-D0819EFF-7A85-4A9B-AD23-D104400FACD8 Q34700590-DB75C2DC-53EF-4D2D-B2E3-7BC86B6EA715 Q35213346-0BBD6C88-6906-4782-958D-45DD7742EEFA Q35229856-E68A27E9-5D91-4AA7-93E8-36DFB86B5CC8 Q35542888-15B9742F-6B09-48B9-9AA2-C8D72B016134 Q35763145-ED4C3857-01B8-464F-AA19-A14B070276FA Q35861006-E54E38BA-1E8B-4D58-8146-4568ECD1BB1E Q36350112-8938296B-7D76-4246-B916-86E1DB2DA5DF Q36514299-F7AC0920-FD0C-4D63-BABE-15FAC2B747B4 Q36803600-DC3D88E2-40E5-4130-8C62-EF30568726F2 Q37632735-AB997ADC-75B4-4A52-B4CA-47D31A830B21 Q38588243-3040605C-5673-4011-BB7E-900052B46482 Q38774491-BC1644F1-60B2-44B4-A237-14C37E60BA24 Q39036272-756E3D16-ED2C-4D4C-A191-BB0B45BEDFB6 Q47738850-2C896BFB-2DB9-4DE2-9F89-426279CAD47C Q59135256-BA181EE4-A0A1-4BD4-B1B0-081F94EC8A58

P2860

Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma

http://www.wikidata.org/entity/Q33183686

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@ast

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@en

type

label

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@ast

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@en

prefLabel

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@ast

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@en

P1433

Q33183686-6EAA0D12-4783-43D3-9E41-F248E0D262E3

P1476

Q33183686-CF7F63CA-E2BB-4CC5-BC25-50F2D519A8D6

P2093

Q33183686-06E67DDE-D50C-4D39-9422-9C60E2C58623

Q33183686-1BB0C2E4-FF3F-493D-9A27-54A09C30A78A

Q33183686-2FEC3CA1-736C-46CE-A298-8EA7A3D699B9

Q33183686-8F71F886-3909-4A67-B887-FB6F168033F0

Q33183686-91B4634E-0707-4E07-830A-9F2C694DF72A

Q33183686-98E59AE2-4D7F-4F81-B50A-3950FCBF1CA4

Q33183686-A323C6D0-5C85-461B-A5CC-5E65C3758C54

Q33183686-C277A0A6-2EEF-4AF3-920F-039C71575D23

Q33183686-CEEF6DF1-62AD-4337-B5B7-8DEF51095FEF

Q33183686-D275B1C1-C049-4C66-836E-EF43ABE587F0

P2860

Q33183686-003844F9-C4AE-43B5-9B69-3557D9D57241

Q33183686-0FD52223-2C78-45A6-9B62-FF62D31B2A37

Q33183686-10D92229-F640-4A47-846C-CB0ECD7FEF9C

Q33183686-13A8A4B1-4B39-4611-AFA6-5FEEF0C223ED

Q33183686-182E183C-F880-4719-AF84-3CA0A157714F

Q33183686-1CBB51DD-5BDF-4EAF-8232-5B1D009B0AA2

Q33183686-1D19C4F0-5D62-4C30-88D0-A95EE5B0248E

Q33183686-210FDDF3-8D9E-4E87-A71D-43C819C0849C

Q33183686-24F759CC-AC93-43A8-977F-5D27D601641A

Q33183686-2E71DCBA-E59E-43D9-AE68-48073BFC6DFA

P304

Q33183686-3B6FF34D-4BBE-46E7-A640-C683FEDE5C6E

P31

Q33183686-BF244F13-4AFB-44D6-8DCD-27FF5C92F5BE

P407

Q33183686-8565AED9-6552-4436-8779-3A2E86754807

P433

Q33183686-BFDE01E0-CE4C-4874-A04A-BE3D9903EE87

P478

Q33183686-EBC336E3-B2C5-4BF6-B83E-1897CDC94EBD

P577

Q33183686-009B1C86-D888-42A2-9A0D-01C60857BE15

P698

Q33183686-0C96E451-F509-4003-B104-2DF373168C1F

P932

Q33183686-87662B32-4B43-483A-A3D3-E95037E78D59

P1433

Clinical Cancer Research

P1476

Nuclear receptor agonists as p ...... agents for human osteosarcoma

@en

P2093

Akira Ishikawa

http://www.w3.org/2001/XMLSchema#string

Anthony Montag

http://www.w3.org/2001/XMLSchema#string

Benjamin Breyer

http://www.w3.org/2001/XMLSchema#string

Hongwei Cheng

http://www.w3.org/2001/XMLSchema#string

Lan Zhou

http://www.w3.org/2001/XMLSchema#string

Michael A Simon

http://www.w3.org/2001/XMLSchema#string

Rex C Haydon

http://www.w3.org/2001/XMLSchema#string

Tao Feng

http://www.w3.org/2001/XMLSchema#string

Terrance Peabody

http://www.w3.org/2001/XMLSchema#string

Tong-Chuan He

http://www.w3.org/2001/XMLSchema#string

P2860

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids

The nuclear receptor superfamily: the second decade

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids

Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

Selective drug resistant human osteosarcoma cell lines.

P304

1288-1294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12006550

http://www.w3.org/2001/XMLSchema#string

P932

4527755

http://www.w3.org/2001/XMLSchema#string